Abimbola Farinde, Pharm.D., is a clinical pharmacist specialist with specializations in psychopharmacology and geriatrics.
Approximately 50,000 Americans are infected with the human immunodeficiency virus (HIV) each year. The HIV infection can ultimately result in the onset of acquired immune deficiency syndrome (AIDS), which can negatively impact the body’s ability to fight disease through the destruction of CD4+ T cells. According to the Center for Disease Control and Prevention, more than 1 million people are currently living with HIV in the United States and about 15,000 individuals died from the disease in 2010, citing an urgent need for more effective detection and treatment regimens. In recent months, the Food and Drug Administration has made noteworthy approvals for the detection and treatment of the HIV. The first breakthrough approval, the Alere Determine, was the first of its kind for the detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 (responsible for most infections) and HIV-2 (primarily found in West Africa) in human serum, plasma, and venous or fingerstick whole blood specimens. Continue reading